Longitudinal Analysis of Humoral and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB Breakthrough Infection and BA.5/BF.7-XBB Reinfection

The rapid mutation of SARS-CoV-2 has led to multiple rounds of large-scale breakthrough infection and reinfection worldwide. However, the dynamic changes of humoral and cellular immunity responses to several subvariants after infection remain unclear. In our study, a 6-month longitudinal immune resp...

Full description

Bibliographic Details
Published in:	Vaccines
Main Authors:	Xun Wang, Meng Zhang, Kaifeng Wei, Chen Li, Jinghui Yang, Shujun Jiang, Chaoyue Zhao, Xiaoyu Zhao, Rui Qiao, Yuchen Cui, Yanjia Chen, Jiayan Li, Guonan Cai, Changyi Liu, Jizhen Yu, Wenhong Zhang, Faren Xie, Pengfei Wang, Yanliang Zhang
Format:	Article
Language:	English
Published:	MDPI AG 2024-04-01
Subjects:	SARS-CoV-2 breakthrough infection reinfection memory B cells IFN-γ
Online Access:	https://www.mdpi.com/2076-393X/12/5/464

Similar Items

Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
by: Shuo Liu, et al.
Published: (2023-12-01)

Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprintingResearch in context
by: Tingting Cui, et al.
Published: (2024-01-01)

Possible threat of the Omicron subvariants XBB.1.5 and BF.7 to the Indian subcontinent: A correspondence
by: Shankhaneel Ghosh, et al.
Published: (2023-03-01)

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination1
by: Hongyu Wang, et al.
Published: (2023-12-01)

Renewed global threat by the novel SARS-CoV-2 variants ‘XBB, BF.7, BQ.1, BA.2.75, BA.4.6’: A discussion
by: Ranjan K. Mohapatra, et al.
Published: (2022-12-01)

COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2
by: Wei-Chun Chen, et al.
Published: (2023-08-01)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
by: Airu Zhu, et al.
Published: (2023-03-01)

Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023
by: Jianpeng Cai, et al.
Published: (2024-12-01)

Dynamic changes of neutralizing antibody and memory T cell responses six months post Omicron XBB reinfection
by: Xin-Jing Zhao, et al.
Published: (2024-10-01)

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1
by: Fanglei Zuo, et al.
Published: (2023-04-01)

Evolutionary analysis of Omicron variant BF.7 and BA.5.2 pandemic in China
by: Yamin Sun, et al.
Published: (2023-03-01)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
by: Rajesh M. Valanparambil, et al.
Published: (2023-11-01)

Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection
by: Jin-Jin Chen, et al.
Published: (2023-04-01)

A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB
by: Yuan Ding, et al.
Published: (2023-03-01)

Clinical characteristics of abruptly increased paediatric patients with Omicron BF.7 or BA.5.2 in Beijing
by: Lei Yu, et al.
Published: (2023-09-01)

SARS-CoV-2 Vaccine Breakthrough Reinfections in Fully Vaccinated Healthcare Workers in Davao City, Philippines: A Retrospective Cohort Study
by: Alfredo A. Hinay, et al.
Published: (2025-07-01)

Comparative pathogenicity of BA.2.12, BA.5.2 and XBB.1 with the Delta variant in Syrian hamsters
by: Sreelekshmy Mohandas, et al.
Published: (2023-06-01)

The epidemiology and phylogenetic trends of Omicron subvariants from BA.5 to XBB.1 in Taiwan
by: Jih-Jin Tsai, et al.
Published: (2024-11-01)

Clinical Characteristics, Breakthrough Infections, and Reinfections with SARS CoV-2 among Healthcare Workers in the Omicron Wave
by: Reyaz Ahmed Khan, et al.
Published: (2025-06-01)

Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7.
by: Yanfang Zhang, et al.
Published: (2023-09-01)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
by: Jingyun Yang, et al.
Published: (2023-06-01)

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
by: Hui Zhao, et al.
Published: (2024-01-01)

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
by: Masayuki Amano, et al.
Published: (2023-10-01)

Immune response and severity of Omicron BA.5 reinfection among individuals previously infected with different SARS-CoV-2 variants
by: Lu Li, et al.
Published: (2023-12-01)

Maternal and neonatal outcomes and clinical laboratory testing of pregnant women with COVID-19 during the BA.5.2/BF.7 surge
by: Jiali Cao, et al.
Published: (2024-12-01)

Severity of COVID-19 sub-lineages XBB/XBB 1.5/XBB1.16, EG.5.1. and JN.1. in England
by: Catherine Quinot, et al.
Published: (2024-08-01)

Retrospective systematic analysis of incidence and severity of COVID-19 reinfection
by: SHI Lei, et al.
Published: (2023-11-01)

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
by: Bradley K. Ackerson, et al.
Published: (2024-12-01)

Assessment of factors influencing outcomes of SARS‐CoV‐2 Omicron subvariants BA.5.2/BF.7 infection in rheumatoid arthritis patients
by: Yan Wang, et al.
Published: (2025-06-01)

Twitter-Based Sentiment Analysis and Topic Modeling of Social Media Posts using Natural Language Processing, to Understand People’s Perspectives Regarding COVID-19 Omicron Subvariants XBB.1.5 and BF.7
by: S.V. Praveen, et al.
Published: (2023-03-01)

Genomic evolution of BA.5.2 and BF.7.14 derived lineages causing SARS-CoV-2 outbreak at the end of 2022 in China
by: Wentao Zhu, et al.
Published: (2023-11-01)

Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain)
by: Laura Ciuffreda, et al.
Published: (2023-12-01)

15 Divergent performance of bivalent BA.5 and monovalent XBB.1.5 COVID-19 vaccines given as annual booster
by: Marianne Shawe-taylor, et al.
Published: (2025-03-01)

Replication Efficiency of SARS-CoV-2 Omicron Subvariants BA.2.75, BA.5, and XBB.1 in Human Mini-Gut Organoids
by: Kei Miyakawa, et al.
Published: (2024-01-01)

Corrigendum: Genomic evolution of BA.5.2 and BF.7.14 derived lineages causing SARS-CoV-2 outbreak at the end of 2022 in China
by: Wentao Zhu, et al.
Published: (2024-03-01)

Seroprevalence of SARS-CoV-2 neutralising antibodies and cross-reactivity to JN.1 one year after the BA.5/BF.7 wave in China
by: Xue-Dong Song, et al.
Published: (2024-03-01)

Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
by: Peter J. Halfmann, et al.
Published: (2024-03-01)

Neutralizing Antibody-Mediated Protection from Prior Delta Variant Infection Against Omicron BA.5 Sub-Lineage Reinfection One Year Later: A Prospective Cohort Study
by: Shihan Zhang, et al.
Published: (2024-10-01)

Delineating the Structure–Dynamics–Binding Differences among BA.1, BA.4/5, and BF.7 SARS-CoV‑2 Variants through Atomistic Simulations: Correlation with Structural and Epidemiological Features
by: Aryaman Joshi, et al.
Published: (2023-10-01)

The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells
by: Joel Sop, et al.
Published: (2025-03-01)